Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Paul Silva who wrote (718)	2/11/1998 12:24:00 PM
From: Mark Bartlett	Respond to of 14101

Paul, This looks very promising to me ... that comment that WF10 is tolerated well when given systematically is very important. Personally I suspect those that will be potential recipients of the drug may be in weakened states - so the fact the drug is well tolerated is very good news. Would it not be interesting if WF10 and Pennsaid could be used in conjunction with each other for the relief of arthritis .... one to re-tune the immune system - the other for chronic pain relief. So many other potential uses for other auto-immune diseases too. Looks to be lots of potential here! Best to all, MB

To: Paul Silva who wrote (718)	2/11/1998 12:46:00 PM
From: READE SMITH	Read Replies (1) \| Respond to of 14101

WF-10 "supercharges" the immune system and presents a "completely new" (ie revolutionary) drug treatment for Aids, Cancer, Transplants, Burn Victims -- etc. That's what today's release really states. Dimethaid has been besieged with calls today asking for a layman's explanation of the study which "demonstrated that WF-10 is a potent inhibitor of antigen presentation by both dendritic cells and monocytes". With the results of this first independent study and follow-up to this weekend's presentation in Switzerland we have reached a whole new plateau for DMX. This is huge -- any Doctors on this thread care to comment?